# Biofidelity

Source: https://onco.cc/companies/biofidelity/  
OnCo record `biofidelity` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Cambridge company developing Enspyre, a way of enriching tumour DNA so blood tests for leftover cancer need far less sequencing.

## Summary

Biofidelity Ltd of Cambridge, UK, is the affiliation of the authors of the 2026 Scientific Reports study of Enspyre, a mutation-enrichment ctDNA assay tested on diluted lung cancer plasma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Biofidelity Ltd
- HQ: Cambridge
- Type: diagnostics

## Sources

- Labrousse et al., Enspyre (Scientific Reports 2026): https://doi.org/10.1038/s41598-026-57421-5

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- key papers: [Enrichment of mutated DNA enables ultra-sensitive ctDNA detection in NSCLC using shallow targeted sequencing](https://onco.cc/key-papers/paper-labrousse-enspyre-sci-rep-2026/)
- drugs: [Enspyre](https://onco.cc/drugs/enspyre-mrd/)

---
JSON: https://onco.cc/api/v1/entities/biofidelity.json